At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab
Your search for bevacizumab returned 10 results
Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
There was no improvement in overall survival with bevacizumab.
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
Substantial improvement observed through month 12, which persisted through month 60, but lessened with fewer treatments
The approval was based on data from the phase 3 KEYNOTE-826 trial.
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.